Analyst Reco. Tandem Diabetes Care, Inc.

Equities

TNDM

US8753722037

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-10 pm EDT			5-day change	1st Jan Change
48.5 ^USD	-0.72%		-6.69%	+63.96%

02:20pm	Oppenheimer Adjusts Price Target on Tandem Diabetes Care to $58 From $47, Maintains Outperform Rating	MT
Jun. 06	Transcript : Tandem Diabetes Care, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 08:00 AM

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Adjusts Price Target on Tandem Diabetes Care to $58 From $47, Maintains Outperform Rating	08:20am	MT
Tandem Diabetes Care Insider Sold Shares Worth $258,400, According to a Recent SEC Filing	Jun. 03	MT
Redburn Atlantic Starts Tandem Diabetes Care With Buy Rating, $60 Price Target	May. 30	MT
Lake Street Adjusts Price Target on Tandem Diabetes Care to $75 From $60, Maintains Buy Rating	May. 22	MT
Stifel Adjusts Price Target on Tandem Diabetes Care to $55 From $45, Maintains Buy Rating	May. 22	MT
Citi Upgrades Tandem Diabetes Care to Buy, Price Target at $57	May. 22	MT
Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Wednesday; Hims & Hers Health, Tesla to Decline	May. 22	MT
UBS Adjusts Price Target on Tandem Diabetes Care to $40 From $28, Maintains Neutral Rating	May. 03	MT
Wells Fargo Upgrades Tandem Diabetes Care to Overweight From Equalweight, Price Target is $45	Apr. 29	MT
Leerink Partners Upgrades Tandem Diabetes Care to Outperform Rating, Price Target is $45	Apr. 25	MT
Stifel Adjusts Price Target on Tandem Diabetes Care to $40 From $37, Maintains Buy Rating	Apr. 23	MT
Stifel Upgrades Tandem Diabetes Care to Buy From Hold, Adjusts Price Target to $37 From $24	Mar. 26	MT
Citigroup Raises Price Target on Tandem Diabetes Care to $31 From $25, Keeps Neutral Rating	Mar. 15	MT
UBS Raises Tandem Diabetes Care Price Target to $28 From $18, Maintains Neutral Rating	Jan. 22	MT
TD Cowen Raises Tandem Diabetes Care Price Target to $35 From $22, Maintains Outperform Rating	Jan. 18	MT
BofA Securities Cuts Price Target on Tandem Diabetes Care to $18 From $33, Keeps Underperform Rating	23-10-18	MT
Citigroup Cuts Tandem Diabetes Care's Price Target to $23 From $31, Keeps Neutral Rating	23-10-02	MT
Jefferies Adjusts Price Target on Tandem Diabetes Care to $45 From $47, Maintains Buy Rating	23-10-02	MT
Citigroup Adjusts Price Target on Tandem Diabetes Care to $31 From $33, Maintains Neutral Rating	23-08-21	MT
Baird Trims Price Target on Tandem Diabetes Care to $32 From $33, Maintains Neutral Rating	23-08-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Tandem Diabetes Care, Inc.

Equities

TNDM

US8753722037

Analyst Reco.

Filters